INTRODUCTION: [(68)Ga]PSMA-11 is a relatively recently introduced radiopharmaceutical for PET-CT imaging of prostate cancer patients. The availability of (68)Ge/(68)Ga generator and PSMA-11 ligand from commercial sources is facilitating the production of the radiopharmaceutical in-house. This paper describes our experience on the preparation of ~200 batches of [(68)Ga]PSMA-11 for conducting PET-CT imaging in patients suspected/suffering from prostate cancer. METHODS: The radiosynthesis of [(68)Ga]PSMA-11 was done in a hospital based nuclear medicine department using (68)Ge/(68)Ga generator and a manual synthesis module, both supplied by Isotope Technologies Garching (ITG), Germany. The production involved the reaction of 5μg (5.3nmol) of PSMA-11 ligand in 1 ml of 0.25M sodium acetate buffer with 4ml of (68)GaCl3 in 0.05M HCl for 5min at 105°C; followed by purification in a C18 cartridge and collection through a 0.22μm pore size filter. RESULTS: The radiochemical yields obtained were consistently high, 93.19%±3.76%, and there was hardly any batch failure. The radiochemical purity of the product was >99% and the product was stable for over 2h; however it was used in patients immediately after preparation. About 200 batches of [(68)Ga]PSMA-11 were prepared during the period and more than 300 patients received the tracer during the 14months of study. No adverse reaction was observed in any of the patients and the image qualities were consistent with literature reports. CONCLUSION: [(68)Ga]PSMA-11 with high radiochemical and radionuclidic purity is conveniently prepared by using a (68)Ge/(68)Ga generator and manual synthesis module. The radiochemical yields are very high; and activity sufficient for 3-4 patients can be prepared in a single batch; multiple batches can be done on the same day and when needed after a gap of 1.5-2h.
INTRODUCTION: [(68)Ga]PSMA-11 is a relatively recently introduced radiopharmaceutical for PET-CT imaging of prostate cancerpatients. The availability of (68)Ge/(68)Ga generator and PSMA-11 ligand from commercial sources is facilitating the production of the radiopharmaceutical in-house. This paper describes our experience on the preparation of ~200 batches of [(68)Ga]PSMA-11 for conducting PET-CT imaging in patients suspected/suffering from prostate cancer. METHODS: The radiosynthesis of [(68)Ga]PSMA-11 was done in a hospital based nuclear medicine department using (68)Ge/(68)Ga generator and a manual synthesis module, both supplied by Isotope Technologies Garching (ITG), Germany. The production involved the reaction of 5μg (5.3nmol) of PSMA-11 ligand in 1 ml of 0.25M sodium acetate buffer with 4ml of (68)GaCl3 in 0.05M HCl for 5min at 105°C; followed by purification in a C18 cartridge and collection through a 0.22μm pore size filter. RESULTS: The radiochemical yields obtained were consistently high, 93.19%±3.76%, and there was hardly any batch failure. The radiochemical purity of the product was >99% and the product was stable for over 2h; however it was used in patients immediately after preparation. About 200 batches of [(68)Ga]PSMA-11 were prepared during the period and more than 300 patients received the tracer during the 14months of study. No adverse reaction was observed in any of the patients and the image qualities were consistent with literature reports. CONCLUSION: [(68)Ga]PSMA-11 with high radiochemical and radionuclidic purity is conveniently prepared by using a (68)Ge/(68)Ga generator and manual synthesis module. The radiochemical yields are very high; and activity sufficient for 3-4 patients can be prepared in a single batch; multiple batches can be done on the same day and when needed after a gap of 1.5-2h.
Authors: Francisco Osvaldo García-Pérez; Jenny Davanzo; Sergio López-Buenrostro; Clara Santos-Cuevas; Guillermina Ferro-Flores; Miguel A Jímenez-Ríos; Anna Scavuzzo; Zael Santana-Ríos; Sevastián Medina-Ornelas Journal: Am J Nucl Med Mol Imaging Date: 2018-10-20
Authors: Sinan Wang; Charles Blaha; Raquel Santos; Tony Huynh; Thomas R Hayes; Denis R Beckford-Vera; Joseph E Blecha; Andrew S Hong; Miko Fogarty; Thomas A Hope; David R Raleigh; David M Wilson; Michael J Evans; Henry F VanBrocklin; Tomoko Ozawa; Robert R Flavell Journal: Mol Pharm Date: 2019-08-16 Impact factor: 4.939
Authors: Robert M Hicks; Jeffry P Simko; Antonio C Westphalen; Hao G Nguyen; Kirsten L Greene; Li Zhang; Peter R Carroll; Thomas A Hope Journal: Radiology Date: 2018-09-18 Impact factor: 11.105
Authors: Christian W Wichmann; Uwe Ackermann; Stan Poniger; Kenneth Young; Benjamin Nguyen; Gordon Chan; John Sachinidis; Andrew M Scott Journal: J Labelled Comp Radiopharm Date: 2020-11-02 Impact factor: 1.921
Authors: Leonardo L Fuscaldi; Danielle V Sobral; Ana Claudia R Durante; Fernanda F Mendonça; Ana Cláudia C Miranda; Marcelo L da Cunha; Luciana Malavolta; Jorge Mejia; Marycel F de Barboza Journal: Pharmaceuticals (Basel) Date: 2021-04-21
Authors: Courtney Lawhn-Heath; Robert R Flavell; David E Korenchan; Timothy Deller; Spencer Lake; Peter R Carroll; Thomas A Hope Journal: Mol Imaging Date: 2018 Jan-Dec Impact factor: 4.488